

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hong Kong Life Sciences and Technologies Group Limited

香港生命科學技術集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8085)

**POLL RESULTS OF ANNUAL GENERAL MEETING
HELD ON 15 SEPTEMBER 2017**

References are made to the circular of Hong Kong Life Sciences and Technologies Group Limited (the “**Company**”) dated 11 July 2017 and the supplemental circular dated 23 August 2017 respectively (the “**Circulars**”) and revised notice of postponed annual general meeting (the “**Notice of AGM**”) dated 23 August 2017, in respect of the annual general meeting of the Company held on 15 September 2017 (the “**AGM**”). Capitalized terms used herein shall have the same meanings as those defined in the Circulars unless defined otherwise herein.

Poll Results of the AGM

The Board is pleased to announce that all the resolutions as set out in the Notice of AGM (except resolution No. 4) were duly passed by the Shareholders by way of poll at the AGM held on 15 September 2017.

As at the date of the AGM, the total number of Shares in issue was 5,688,396,805 Shares, which was also the total number of Shares entitling the Shareholders to attend and vote for or against the resolutions at the AGM. No Shareholder was entitled to attend and abstain from voting on the resolutions and no Shareholder was required to abstain from voting in favour of the resolutions according to Rule 17.47A of the GEM Listing Rules.

The Company’s Hong Kong branch share registrar and transfer office, Tricor Standard Limited, was appointed as the scrutineer for the vote-taking at the AGM.

The poll results in respect of each of the resolutions were as follows:

ORDINARY RESOLUTIONS		NUMBER OF VOTES (APPROXIMATE PERCENTAGE)	
		FOR	AGAINST
1.	To receive and consider the audited financial statements, the Directors' report and the independent auditors' report for the year ended 31 March 2017.	2,523,723,136 (100%)	0 (0%)
2.	(a) To re-elect Mr. Zhang James Jian Yuan as an independent non-executive Director;	2,523,723,136 (100%)	0 (0%)
	(b) To re-elect Mr. Lu Zhiqiang as an executive Director;	2,523,723,136 (100%)	0 (0%)
	(c) To re-elect Mr. Chui Kwong Kau as an executive Director;	2,523,723,136 (100%)	0 (0%)
	(d) To re-elect Mr. Chan Yun Hing as an independent non-executive Director;	2,523,723,136 (100%)	0 (0%)
	(e) To re-elect Dr. Sun Yu as an executive Director; and	2,523,721,136 (100%)	0 (0%)
	(f) To authorise the board of Directors to fix the Directors' remuneration.	2,523,723,136 (100%)	0 (0%)
3.	To re-appoint Pan-China (H.K.) CPA Limited as the auditors of the Company and to authorise the board of Directors to fix its remuneration.	2,523,723,136 (100%)	0 (0%)
4.	To grant a general mandate to the Directors to allot, issue and deal with additional shares up to 20% of the issued share capital of the Company.	411,763,900 (16.32%)	2,111,959,236 (83.68%)
5.	To grant a general mandate to the Directors to repurchase the Company's shares up to 10% of the issued share capital of the Company.	2,523,723,136 (100%)	0 (0%)
6.	To extend the general mandate to issue new shares by adding the number of shares repurchased.	2,523,723,136 (100%)	0 (0%)

As more than 50% of the votes were cast in favour of the resolutions Nos. 1, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), 3, 5 and 6, these resolutions were duly passed by the Shareholders as ordinary resolutions at the AGM.

As more than 50% of the votes were cast against resolution No. 4, this resolution was not passed by the Shareholders as an ordinary resolution at the AGM.

By order of the Board
Hong Kong Life Sciences and Technologies Group Limited
Lu Zhiqiang
Executive Director and Chief Executive Officer

Hong Kong, 15 September 2017

As at the date of this announcement, the Board comprises (i) six executive Directors, namely Mr. David Lin Kao Kun, Mr. Lu Zhiqiang, Mr. Chui Kwong Kau, Mr. Jiang Hongqing, Ms. Li Mei and Dr. Sun Yu; (ii) one non-executive Director, namely Ms. Lam Kuo; and (iii) four independent non-executive Directors, namely Mr. Hung Yat Ming, Mr. Chan Yun Hing, Mr. Gui Qiangfang and Mr. Zhang James Jian Yuan.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at <http://www.hkgem.com> for a minimum period of seven days from the date of its publication and on the Company’s website at <http://www.hklifesciences.com>.